(Q44373980)

English

Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia

scientific article published in January 1991

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

author name string

P Hörnsten

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

M Hedenus

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

C Malm

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

publication date

1 January 1991

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

480-483

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Acute myelogenous leukemia: recent advances in therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of acute non-lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of acute myelogenous leukemia in children and adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose cytosine arabinoside therapy for refractory leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of acute myelogenous leukemia in adults.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mitozantrone and high-dose cytarabine in adult acute myeloid leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1934252

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00685827

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44373980&oldid=2206601685"